FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014284922> ?p ?o ?g. }

• W2014284922 endingPage "2466" @default.
• W2014284922 startingPage "2458" @default.
• W2014284922 abstract "The current study was conducted to determine the effect of goserelin and bicalutamide on progression-free survival (PFS) in patients with epithelial ovarian cancer who were in second or greater complete disease remission.Patients received bicalutamide at a dose of 50 mg orally daily and goserelin at a dose of 3.6 mg subcutaneously every 4 weeks. CA 125 was obtained monthly, with computed tomography performed every 3 months. Correlative studies included serum luteinizing hormone, follicle-stimulating hormone, vascular endothelial growth factor, free testosterone, and androstenedione and the germline polymorphisms CYP19A1 and androgen receptor.Between October of 2000 and October of 2002, 35 patients were enrolled. Three patients (9%) received therapy at the time of first disease remission and were removed from the study, and 1 patient (3%) was removed for liver function test abnormalities. The most frequent toxicities were grade 1 alkaline phosphatase (54%), fatigue (57%), and hot flashes (42%) based on the National Cancer Institute common toxicity scale, version 2.0. The PFS for patients receiving protocol therapy in second disease remission (21 patients) was 11.4 months (95% confidence interval [95% CI], 10.2-12.6 months). The PFS for patients receiving protocol therapy in third or fourth disease remission (11 patients) was 11.9 months (95% CI, 10.8-14.1 months). The percentage of patients remaining in second disease remission at given times are: 100% at 3 months, 100% at 6 months, 72% at 9 months, 47% at 12 months, 28% at 15 months, 22% at 18 months, 19% at 21 months, and 13% at 24 months. There were no associations noted between androgen receptor repeat number, genotype, allelotype, or haplotypes and PFS.The use of goserelin and bicalutamide did not appear to prolong PFS in patients with epithelial ovarian cancer in second or greater complete disease remission. The number of patients in disease remission at given time points may serve as a clinical trial endpoint for future studies of consolidation therapy." @default.
• W2014284922 created "2016-06-24" @default.
• W2014284922 creator A5001429608 @default.
• W2014284922 creator A5005037311 @default.
• W2014284922 creator A5016423289 @default.
• W2014284922 creator A5016553275 @default.
• W2014284922 creator A5019663026 @default.
• W2014284922 creator A5032196793 @default.
• W2014284922 creator A5036444245 @default.
• W2014284922 creator A5045417042 @default.
• W2014284922 creator A5054602117 @default.
• W2014284922 creator A5073323475 @default.
• W2014284922 creator A5079072671 @default.
• W2014284922 creator A5090740287 @default.
• W2014284922 date "2007-01-01" @default.
• W2014284922 modified "2023-10-16" @default.
• W2014284922 title "A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission" @default.
• W2014284922 cites W1487923227 @default.
• W2014284922 cites W1984132456 @default.
• W2014284922 cites W2004635842 @default.
• W2014284922 cites W2005140082 @default.
• W2014284922 cites W2009971333 @default.
• W2014284922 cites W2011092023 @default.
• W2014284922 cites W2024675548 @default.
• W2014284922 cites W2031082289 @default.
• W2014284922 cites W2032622871 @default.
• W2014284922 cites W2037753918 @default.
• W2014284922 cites W2041035879 @default.
• W2014284922 cites W2077361748 @default.
• W2014284922 cites W2092678754 @default.
• W2014284922 cites W2101065984 @default.
• W2014284922 cites W2106726143 @default.
• W2014284922 cites W2109919831 @default.
• W2014284922 cites W2110755408 @default.
• W2014284922 cites W2126333580 @default.
• W2014284922 cites W2130941707 @default.
• W2014284922 cites W2137849078 @default.
• W2014284922 cites W2151050516 @default.
• W2014284922 cites W2154175915 @default.
• W2014284922 cites W2158104948 @default.
• W2014284922 cites W2165628351 @default.
• W2014284922 cites W2171467390 @default.
• W2014284922 cites W2999391015 @default.
• W2014284922 doi "https://doi.org/10.1002/cncr.23072" @default.
• W2014284922 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17918264" @default.
• W2014284922 hasPublicationYear "2007" @default.
• W2014284922 type Work @default.
• W2014284922 sameAs 2014284922 @default.
• W2014284922 citedByCount "42" @default.
• W2014284922 countsByYear W20142849222012 @default.
• W2014284922 countsByYear W20142849222013 @default.
• W2014284922 countsByYear W20142849222014 @default.
• W2014284922 countsByYear W20142849222015 @default.
• W2014284922 countsByYear W20142849222016 @default.
• W2014284922 countsByYear W20142849222017 @default.
• W2014284922 countsByYear W20142849222018 @default.
• W2014284922 countsByYear W20142849222019 @default.
• W2014284922 countsByYear W20142849222020 @default.
• W2014284922 countsByYear W20142849222021 @default.
• W2014284922 countsByYear W20142849222022 @default.
• W2014284922 countsByYear W20142849222023 @default.
• W2014284922 crossrefType "journal-article" @default.
• W2014284922 hasAuthorship W2014284922A5001429608 @default.
• W2014284922 hasAuthorship W2014284922A5005037311 @default.
• W2014284922 hasAuthorship W2014284922A5016423289 @default.
• W2014284922 hasAuthorship W2014284922A5016553275 @default.
• W2014284922 hasAuthorship W2014284922A5019663026 @default.
• W2014284922 hasAuthorship W2014284922A5032196793 @default.
• W2014284922 hasAuthorship W2014284922A5036444245 @default.
• W2014284922 hasAuthorship W2014284922A5045417042 @default.
• W2014284922 hasAuthorship W2014284922A5054602117 @default.
• W2014284922 hasAuthorship W2014284922A5073323475 @default.
• W2014284922 hasAuthorship W2014284922A5079072671 @default.
• W2014284922 hasAuthorship W2014284922A5090740287 @default.
• W2014284922 hasBestOaLocation W20142849221 @default.
• W2014284922 hasConcept C121608353 @default.
• W2014284922 hasConcept C126322002 @default.
• W2014284922 hasConcept C126894567 @default.
• W2014284922 hasConcept C141071460 @default.
• W2014284922 hasConcept C2778043895 @default.
• W2014284922 hasConcept C2779322244 @default.
• W2014284922 hasConcept C2780192828 @default.
• W2014284922 hasConcept C2780962315 @default.
• W2014284922 hasConcept C530470458 @default.
• W2014284922 hasConcept C61367390 @default.
• W2014284922 hasConcept C71924100 @default.
• W2014284922 hasConcept C90924648 @default.
• W2014284922 hasConceptScore W2014284922C121608353 @default.
• W2014284922 hasConceptScore W2014284922C126322002 @default.
• W2014284922 hasConceptScore W2014284922C126894567 @default.
• W2014284922 hasConceptScore W2014284922C141071460 @default.
• W2014284922 hasConceptScore W2014284922C2778043895 @default.
• W2014284922 hasConceptScore W2014284922C2779322244 @default.
• W2014284922 hasConceptScore W2014284922C2780192828 @default.
• W2014284922 hasConceptScore W2014284922C2780962315 @default.
• W2014284922 hasConceptScore W2014284922C530470458 @default.
• W2014284922 hasConceptScore W2014284922C61367390 @default.
• W2014284922 hasConceptScore W2014284922C71924100 @default.

• next